SynthesisCancer medicine2019

Safety and efficacy profile of cyclin-dependent kinases 4/6 inhibitor palbociclib in cancer therapy: A meta-analysis of clinical trials.

Linghong Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.